{
    "clinical_study": {
        "@rank": "121200", 
        "arm_group": [
            {
                "arm_group_label": "Vitamin D3", 
                "arm_group_type": "Active Comparator", 
                "description": "The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3; producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Oily drops as placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "In this randomized, double-blind, placebo-controlled trial we plan to enrol 200 vitamin D\n      deficient hypertensive patients. Our main objective is to evaluate whether vitamin D3\n      supplementation with 2,800 IU daily for 8 weeks has an effect on 24-hour systolic ambulatory\n      blood pressure (ABP) compared to placebo. In addition, we also aim to evaluate whether\n      vitamin D3 supplementation alters 24-hour diastolic ABP, pulse wave velocity,\n      N-terminal-pro-brain natriuretic peptide (NT-pro-BNP), corrected QT interval (Bazett\n      formula), renin, aldosterone, 24-hour urinary albumin excretion, HOMA-IR (HOmeostatic Model\n      Assessment: Insulin Resistance), triglycerides and HDL-cholesterol."
        }, 
        "brief_title": "Styrian Vitamin D Hypertension Trial", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Arterial Hypertension", 
            "Vitamin D Deficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Vitamin D Deficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  25-hydroxyvitamin D levels below 30 ng/ml (75 nmol/L)\n\n          -  Arterial hypertension defined according to recent guidelines as an average office\n             blood pressure on at least two occasions of systolic \u2265 140 and/or diastolic \u2265 90 mmHg\n             or a mean 24-hour ABP of systolic \u2265 125 and/or diastolic \u2265 80, or a home blood\n             pressure of systolic \u2265 130 and/or diastolic \u2265 85 or ongoing antihypertensive\n             treatment which was initiated due to arterial hypertension\n\n          -  Age of \u2265 18 years\n\n          -  Written informed consent.\n\n        Exclusion Criteria:\n\n          -  Hypercalcemia defined a serum calcium >2.65 mmol/L\n\n          -  Pregnancy or lactating women\n\n          -  Drug intake as part of another clinical study\n\n          -  Acute coronary syndrome or cerebrovascular events in the previous 2 weeks\n\n          -  Glomerular filtration rate (GFR) according to the MDRD formula < 15 ml/min/1.73m\u00b2\n\n          -  Systolic 24-hour ABP > 160 mm Hg or < 120 mm Hg\n\n          -  Diastolic 24-hour ABP > 100 mm Hg\n\n          -  Change of antihypertensive treatment (drugs and/or lifestyle) in the previous 4 weeks\n             or planned changes of antihypertensive treatment during the study\n\n          -  Any disease with an estimated life expectancy below 1 year\n\n          -  Any clinically significant acute disease requiring drug treatment\n\n          -  Chemotherapy or radiation therapy during the study\n\n          -  Regular intake of more than 880 International Units (IU) vitamin D per day in the\n             last four weeks before study entry or during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02136771", 
            "org_study_id": "EudraCT no:2009-018125-70", 
            "secondary_id": "2009-018125-70"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vitamin D3", 
                "description": "The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3, producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks", 
                "intervention_name": "Vitamin D3", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "contact": {
                "email": "stefan.pilz@medunigraz.at", 
                "last_name": "Stefan Pilz, MD, PhD", 
                "phone": "+43 650 9103667"
            }, 
            "contact_backup": {
                "email": "martin.gaksch@medunigraz.at", 
                "last_name": "Martin Gaksch, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Graz", 
                    "country": "Austria", 
                    "zip": "8036"
                }, 
                "name": "Medical University of Graz"
            }, 
            "investigator": [
                {
                    "last_name": "Stefan Pilz, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Andreas Tomaschitz, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Katharina Kienreich, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Martin Gaksch, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "Styrian Vitamin D Hypertension Trial: A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Effects of Vitamin D Supplementation on Systolic Ambulatory Blood Pressure in Vitamin D Deficient Hypertensive Patients", 
        "overall_contact": {
            "email": "stefan.pilz@medunigraz.at", 
            "last_name": "Stefan Pilz, MD, PhD", 
            "phone": "+43 650 9103667"
        }, 
        "overall_contact_backup": {
            "email": "martin.gaksch@medunigraz.at", 
            "last_name": "Martin Gaksch, MD"
        }, 
        "overall_official": {
            "affiliation": "Medical University of Graz", 
            "last_name": "Stefan Pilz, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "24-hour systolic ambulatory blood pressure", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02136771"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "24-hour diastolic ambulatory blood pressure", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "N-terminal-pro-brain natriuretic peptide (NT-pro-BNP)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "corrected QT interval (Bazett formula)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Plasma renin concentration", 
                "measure": "Renin", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Plasma aldosterone concentration", 
                "measure": "Aldosterone", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "24-hour urinary albumin excretion", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "HOMA-IR (HOmeostatic Model Assessment: Insulin Resistance)", 
                "measure": "HOMA-IR", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Triglycerides", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "HDL-cholesterol", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Pulse wave velocity", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Medical University of Graz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Graz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}